Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn’s disease

Table 1 Patient demographic and clinical characteristic according to response to anti-TNF treatment

Characteristics	Responders	Partial responders	Primarily non-responders
n (%)	72 (67.29)	22 (21.57)	13 (14.74)
Age (yr, mean ± SD)	34.10±11.63	32.23 ± 13.31	39.09 ± 15.60
Sex (%)
Male	30 (41.67)	14 (63.64)	10 (76.92)
Female	42 (62.69)	8 (36.36)	3 (23.08)
C-reactive protein (mg/dL, mean ± SD)
Baseline	3.10 ± 2.03	4.13 ± 2.31	6.86 ± 2.89
After treatment	0.88 ± 1.84	2.21 ± 2.69	3.96 ± 2.81
δC-reactive protein (%)	80.44 ± 22.42	71.94 ± 45.74	58.04 ± 22.63
Duration of disease (yr)	6.38 ± 5.91	5.71 ± 3.77	4.00 ± 3.13
Infliximab dose (mg/kg)	5	5	5
Location
L2	24 (33.34)	3 (13.64)	2 (15.38)
L3	45 (62.50)	19 (86.36)	11 (84.62)
L4	3 (4.48)	0	0
Behavior
B1	31 (43.06)	7 (31.82)	5 (38.46)
B2	13 (18.06)	6 (27.27)	2 (15.38)
B3	28 (38.89)	9 (40.91)	6 (46.15)

Table 2 Genotype and allele frequencies of rs2910164, rs11614913, and rs188519172 polymorphisms in Crohn’s disease patients according to response to anti-TNF treatment

Genotype	Complete responders (n = 72)	Partial responders (n = 22)	P value; OR (95%CI)	Non-responders (n = 13)	P value; OR (95%CI)
miR-146a, rs2910164
GG	70 (97.22)	21 (95.45)	1.0 (reference)	12 (92.31)	1.0 (reference)
GC	2 (2.78)	1 (4.54)	0.55; 1.67 (0.14-19.32)	1 (7.69)	0.39; 2.92 (0.25-34.76)
CC	0	0	-	0	-
miR-196a, rs11614913
CC	33 (45.83)	5 (22.73)	1.0 (reference)	5 (38.46)	1.0 (reference)
CT	32 (44.45)	13 (59.09)	0.11; 2.7 (0.86-8.39)	5 (38.46)	1.0; 1.03 (0.27-3.91)
TT	7 (9.73)	4 (18.18)	0.18; 3.78 (0.8-17.73)	3 (23.08)	0.34; 2.83 (0.54-14.69)
miR-224, rs188519172
AA	38 (52.78)	9 (40.9)	1.0 (reference)	7 (53.84)	1.0 (reference)
AG	29 (40.28)	11 (50)	0.44; 1.60 (0.59-4.37)	4 (30.76)	0.75; 0.75 (0.20-2.80
GG	5 (6.94)	2 (9.09)	0.62; 1.69 (0.28-10.16)	2 (15.38)	0.59; 2.17 (0.35-13.51)